Clinical Trial

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-26.
Status change: Not Yet Recruiting → Recruiting 2024-06-20
Trial Details
NCT Number NCT06341335
Lead Sponsor Akeso
Conditions Gastric and Gastroesophageal Junction Adenocarcinoma
Enrollment 506 participants
Start Date 2024-06-19
Primary Completion 2026-11 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2024-06-24